AR111497A1 - Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estos - Google Patents
Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estosInfo
- Publication number
- AR111497A1 AR111497A1 ARP180101105A ARP180101105A AR111497A1 AR 111497 A1 AR111497 A1 AR 111497A1 AR P180101105 A ARP180101105 A AR P180101105A AR P180101105 A ARP180101105 A AR P180101105A AR 111497 A1 AR111497 A1 AR 111497A1
- Authority
- AR
- Argentina
- Prior art keywords
- amino acid
- aqueous pharmaceutical
- pharmaceutical formulation
- antigen binding
- binding portion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
En la presente se describen formulaciones farmacéuticas acuosas que comprenden denosumab u otro anticuerpo monoclonal anti-RANKL humano o parte de este, y características de pH, sistemas amortiguadores e inhibidores de agregación de aminoácidos. También se describe una presentación de la formulación para su uso, por ejemplo, en un recipiente de único uso, una jeringa de único uso, o un recipiente de vidrio, métodos de uso de las formulaciones y artículos para evitar o tratar enfermedades, y kits relacionados. Reivindicación 1: Una formulación farmacéutica acuosa que comprende (i) un anticuerpo monoclonal activador de receptores anti-humanos de ligando kappa-B de factor nuclear (anti-RANKL) humano, o una porción de fijación al antígeno de este, y (ii) un inhibidor de agregación de aminoácidos. Reivindicación 3: La formulación farmacéutica acuosa de la reivindicación 1 ó 2, en donde el anticuerpo anti-RANKL, o porción de fijación al antígeno de este, comprende un dominio variable de la cadena ligera que comprende una secuencia CDR1 de la cadena ligera que comprende la secuencia de aminoácidos indicada en SEQ ID Nº 5. Reivindicación 17: La formulación farmacéutica acuosa de la reivindicación 15 ó 16, en donde la concentración del anticuerpo o porción de fijación al antígeno de este está en un intervalo de aproximadamente 100 a aproximadamente 140 mg/ml. Reivindicación 20: La formulación farmacéutica acuosa de cualquiera de las reivindicaciones 1 y 3 a 19, en donde el inhibidor de agregación de aminoácidos comprende un aminoácido que comprende una cadena lateral con carga, un aminoácido aromático o un aminoácido hidrófobo. Reivindicación 32: La formulación farmacéutica acuosa de la reivindicación 31, que comprende HCl L-arginina o HCl L-lisina. Reivindicación 176: Un método para prevenir un evento óseo (SRE) en un paciente que lo necesite que comprende administrar una cantidad eficaz de una formulación de acuerdo con las reivindicaciones 1 a 85 y 172. Reivindicación 177: El método de la reivindicación 176, en donde el SRE se selecciona del grupo que consiste en una fractura patológica, tratamiento de radiación al hueso, cirugía al hueso y compresión de la médula espinal. Reivindicación 178: El método de la reivindicación 176 ó 177, en donde el paciente tiene una metástasis ósea de un tumor sólido. Reivindicación 179: El método de la reivindicación 178, en donde el tumor sólido se selecciona de cáncer de mama, cáncer de próstata, cáncer de pulmón, cáncer pulmonar de células no pequeñas y carcinoma de células renales. Reivindicación 180: El método de la reivindicación 178 ó 179, en donde el paciente tiene mieloma múltiple. Reivindicación 208: Un método para mejorar la estabilidad de una formulación farmacéutica acuosa que comprende un anticuerpo monoclonal activador de receptores anti-humanos de ligando kappa-B de factor nuclear (anti-RANKL) o una porción de fijación al antígeno de este, que comprende: preparar dicha formulación farmacéutica acuosa que comprende dicho anticuerpo monoclonal activador de receptores anti-humanos de ligando kappa-B de factor nuclear (anti-RANKL) humano o una porción de fijacion al antígeno de este en una mezcla con un inhibidor de agregación de aminoácidos, en donde dicha formulación farmacéutica acuosa demuestra la mejora de la estabilidad con el inhibidor de agregación de aminoácidos en comparación con una formulación farmacéutica acuosa equivalente sin el inhibidor de agregación de aminoácidos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762492056P | 2017-04-28 | 2017-04-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR111497A1 true AR111497A1 (es) | 2019-07-17 |
Family
ID=62165668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180101105A AR111497A1 (es) | 2017-04-28 | 2018-04-27 | Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estos |
Country Status (31)
Country | Link |
---|---|
US (2) | US11192952B2 (es) |
EP (2) | EP3615066B1 (es) |
JP (3) | JP7190822B2 (es) |
KR (1) | KR20190140464A (es) |
CN (1) | CN110621342A (es) |
AR (1) | AR111497A1 (es) |
AU (1) | AU2018260750A1 (es) |
BR (1) | BR112019022188A2 (es) |
CA (1) | CA3054165A1 (es) |
CL (3) | CL2019003032A1 (es) |
CO (1) | CO2019011463A2 (es) |
CR (1) | CR20190538A (es) |
DK (1) | DK3615066T3 (es) |
EA (1) | EA201992570A1 (es) |
FI (1) | FI3615066T3 (es) |
HR (1) | HRP20240167T1 (es) |
IL (2) | IL293127B1 (es) |
JO (1) | JOP20190255A1 (es) |
LT (1) | LT3615066T (es) |
MA (1) | MA48462A (es) |
MY (1) | MY202479A (es) |
PE (1) | PE20200343A1 (es) |
PH (1) | PH12019502444A1 (es) |
PL (1) | PL3615066T3 (es) |
PT (1) | PT3615066T (es) |
RS (1) | RS65299B1 (es) |
SG (1) | SG11201909998TA (es) |
SI (1) | SI3615066T1 (es) |
TN (2) | TN2021000055A1 (es) |
UY (1) | UY37707A (es) |
WO (1) | WO2018200918A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3120190A1 (en) * | 2018-11-16 | 2020-05-22 | Samsung Bioepis Co., Ltd. | Stable liquid composition comprising protein |
CN109374779A (zh) * | 2018-12-17 | 2019-02-22 | 杭州奕安济世生物药业有限公司 | 一种蔗糖含量的快速检测方法 |
EP3927729A4 (en) | 2019-02-18 | 2023-10-11 | Eli Lilly and Company | THERAPEUTIC ANTIBODY FORMULATION |
CN111704670B (zh) * | 2020-08-18 | 2020-11-03 | 迈威(上海)生物科技股份有限公司 | 重组抗RANKL抗体IgG2型的二硫键异构体及其纯化方法 |
CA3218542A1 (en) * | 2021-05-12 | 2022-11-17 | Hua Ying | Antigen binding molecule specifically binding to rankl and ngf, and medical use thereof |
IL310275A (en) | 2021-08-12 | 2024-03-01 | Amgen Inc | Antibody formulations |
WO2023092177A1 (en) * | 2021-11-23 | 2023-06-01 | Adalta Limited | Rank-l binding molecules |
WO2023179791A1 (en) * | 2022-03-24 | 2023-09-28 | Angitia Biomedicines Limited | Treatment of musculoskeletal disorders |
WO2024064878A1 (en) | 2022-09-23 | 2024-03-28 | The University Of North Carolina At Chapel Hill | Methods and compositions for the treatment of melanoma |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2087908T (pt) | 2001-06-26 | 2018-07-16 | Amgen Inc | Anticorpos contra opgl |
PE20070684A1 (es) | 2005-11-14 | 2007-08-06 | Amgen Inc | MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP |
WO2008079290A2 (en) * | 2006-12-21 | 2008-07-03 | Amgen Inc | Stable buffered formulations containing polypeptides |
WO2009002521A2 (en) | 2007-06-25 | 2008-12-31 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
EA201001223A1 (ru) * | 2008-02-07 | 2011-06-30 | Эмджен Инк. | Стабилизированные белковые композиции |
CL2009001735A1 (es) | 2008-08-19 | 2010-02-19 | Regeneron Pharma | Anticuerpo humano o fragmento de union a antigeno del mismo que une e inhibe actividad de ligando del activador del receptor de nf-kb (rankl); adn codificante; vector de expresion; metodo para producir dicho anticuerpo; composicion farmaceutica que lo comprende; uso para atenuar o inhibir enfermedad o condicion mediada por rankl |
US9265834B2 (en) | 2009-03-05 | 2016-02-23 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
RU2600847C2 (ru) | 2010-05-10 | 2016-10-27 | Интас Биофармасьютикалс Лимитед | Жидкий состав полипептидов, содержащих fc-домен иммуноглобулина |
EP2433644A1 (en) | 2010-09-22 | 2012-03-28 | IMBA-Institut für Molekulare Biotechnologie GmbH | Breast cancer therapeutics |
JP2014510152A (ja) | 2011-04-07 | 2014-04-24 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 粘度が低減された処方物 |
EP2771033A4 (en) | 2011-10-28 | 2016-02-17 | Integritybio Inc | PROTEIN FORMULATIONS CONTAINING AMINO ACIDS |
TWI679019B (zh) | 2013-04-29 | 2019-12-11 | 法商賽諾菲公司 | 抗il-4/抗il-13之雙特異性抗體調配物 |
CN103965357B (zh) | 2013-12-31 | 2016-08-17 | 嘉和生物药业有限公司 | 一种抗人rankl抗体 |
WO2015134406A1 (en) * | 2014-03-03 | 2015-09-11 | La Jolla Biologics, Inc. | Stable aqueous recombinant protein formulations |
BR112016025126B1 (pt) | 2014-05-07 | 2024-02-15 | Takeda Pharmaceutical Company Limited | Composição aquosa compreendendo anticorpo neutralizante de gmcsf, e uso da mesma |
-
2017
- 2017-06-16 JO JOP/2019/0255A patent/JOP20190255A1/ar unknown
-
2018
- 2018-04-27 HR HRP20240167TT patent/HRP20240167T1/hr unknown
- 2018-04-27 WO PCT/US2018/029728 patent/WO2018200918A1/en active Application Filing
- 2018-04-27 MY MYPI2019006326A patent/MY202479A/en unknown
- 2018-04-27 TN TNP/2021/000055A patent/TN2021000055A1/en unknown
- 2018-04-27 RS RS20240313A patent/RS65299B1/sr unknown
- 2018-04-27 MA MA048462A patent/MA48462A/fr unknown
- 2018-04-27 BR BR112019022188-3A patent/BR112019022188A2/pt unknown
- 2018-04-27 TN TNP/2019/000297A patent/TN2019000297A1/en unknown
- 2018-04-27 EA EA201992570A patent/EA201992570A1/ru unknown
- 2018-04-27 EP EP18724690.5A patent/EP3615066B1/en active Active
- 2018-04-27 UY UY0001037707A patent/UY37707A/es unknown
- 2018-04-27 SI SI201831067T patent/SI3615066T1/sl unknown
- 2018-04-27 IL IL293127A patent/IL293127B1/en unknown
- 2018-04-27 CN CN201880028012.1A patent/CN110621342A/zh active Pending
- 2018-04-27 FI FIEP18724690.5T patent/FI3615066T3/fi active
- 2018-04-27 AU AU2018260750A patent/AU2018260750A1/en active Pending
- 2018-04-27 JP JP2018086261A patent/JP7190822B2/ja active Active
- 2018-04-27 PL PL18724690.5T patent/PL3615066T3/pl unknown
- 2018-04-27 PT PT187246905T patent/PT3615066T/pt unknown
- 2018-04-27 AR ARP180101105A patent/AR111497A1/es unknown
- 2018-04-27 LT LTEPPCT/US2018/029728T patent/LT3615066T/lt unknown
- 2018-04-27 EP EP22206709.2A patent/EP4190355A1/en active Pending
- 2018-04-27 KR KR1020197034225A patent/KR20190140464A/ko active IP Right Grant
- 2018-04-27 DK DK18724690.5T patent/DK3615066T3/da active
- 2018-04-27 CA CA3054165A patent/CA3054165A1/en not_active Abandoned
- 2018-04-27 CR CR20190538A patent/CR20190538A/es unknown
- 2018-04-27 SG SG11201909998T patent/SG11201909998TA/en unknown
- 2018-04-27 PE PE2019002120A patent/PE20200343A1/es unknown
- 2018-04-27 US US16/608,375 patent/US11192952B2/en active Active
-
2019
- 2019-08-14 IL IL268704A patent/IL268704B/en unknown
- 2019-10-16 CO CO2019011463A patent/CO2019011463A2/es unknown
- 2019-10-23 CL CL2019003032A patent/CL2019003032A1/es unknown
- 2019-10-28 PH PH12019502444A patent/PH12019502444A1/en unknown
-
2020
- 2020-07-31 CL CL2020002012A patent/CL2020002012A1/es unknown
-
2021
- 2021-11-18 US US17/529,794 patent/US11873343B2/en active Active
-
2022
- 2022-01-14 JP JP2022004150A patent/JP7356525B2/ja active Active
-
2023
- 2023-08-10 JP JP2023130715A patent/JP2023166396A/ja active Pending
- 2023-08-24 CL CL2023002505A patent/CL2023002505A1/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR111497A1 (es) | Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estos | |
EA201992590A1 (ru) | Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения | |
BR112019008010A2 (pt) | anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica | |
CN108136039A (zh) | 用于光免疫疗法的组合物、联用及相关方法 | |
RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
US10232025B2 (en) | Method for minimising progression of cancer in companion animals | |
SI2691112T1 (en) | STABILITY FORMULATION PROTITELES FOR HUMAN PROGRAMMED DEPRESSOR RECEPTOR PD-1 AND RELATED HEALTH | |
KR20180128496A (ko) | 글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에 의한 암 면역요법 | |
AR085955A1 (es) | Proteinas de union al antigeno | |
AR062840A1 (es) | Terapia tumoral con una combinacion de anticuerpos anti receptor del factor de crecimiento epidermico (her2) | |
KR20200112867A (ko) | 길항적 항-pd-1 항체로 암을 치료하는 방법 | |
JP2014500278A (ja) | 二重特異性scFvコンジュゲートの投薬量および投与 | |
CN105749276A (zh) | Cd37抗体在cll血液样品中的优良效力 | |
CN103890007A (zh) | 神经调节蛋白抗体及其用途 | |
FI3463436T3 (fi) | Rokote yhdistelmänä immuunivasteen tarkastuspisteen estäjän kanssa käytettäväksi hoidettaessa syöpää | |
Caballero et al. | Safety and immunogenicity of a human epidermal growth factor receptor 1 (HER1)-based vaccine in prostate castration-resistant carcinoma patients: a dose-escalation phase I study trial | |
Chung et al. | Viral nanoparticle vaccines against S100A9 reduce lung tumor seeding and metastasis | |
RU2016144190A (ru) | Стабильные белковые препараты, содержащие молярный избыток сорбитола | |
AU2015264114A1 (en) | Methods for treating cancer with anti BiP or anti MICA antibodies | |
WO2018209017A1 (en) | Cancer treatment with a cxcl12 signaling inhibitor and an immune checkpoint inhibitor | |
Chaganty et al. | Redirecting host preexisting influenza A virus immunity for cancer immunotherapy | |
JP7467429B2 (ja) | 標的化部分-薬物グラフト化免疫細胞組成物および使用方法 | |
JP2023551432A (ja) | グロボ系列抗原による免疫モジュレーションによる活動性がん免疫療法 | |
WO2021058763A1 (en) | Anti-müllerian inhibiting substance antibodies and uses thereof | |
RU2463667C2 (ru) | Способ иммунотерапии опухолей в эксперименте |